Status:
UNKNOWN
Contrast Enhanced Endoscopic Ultrasound in Pancreas Lesions
Lead Sponsor:
Cedars-Sinai Medical Center
Conditions:
Pancreatitis
Pancreas Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine whether quantitative contrast-enhanced endoscopic ultrasound (CE-EUS) improves the evaluation of pancreas tumors and precursor lesions, including cysts, compa...
Detailed Description
The study is a prospective trial of CE- EUS in which the conventional EUS that is part of standard clinical care is conducted after injection of intravenous contrast agent. The study population will ...
Eligibility Criteria
Inclusion
- Patients undergoing endoscopic ultrasound for pancreatic indications
- Patients must have unexplained pancreatitis, pancreas mass(es), or pancreatic cystic lesions or worrisome clinical, imaging or laboratory findings
Exclusion
- Patients \<18 years of age, pregnant women, and lactating mothers will be excluded.
- Subjects with unstable cardiopulmonary condition will be excluded (acute myocardial infarction, acute coronary syndromes, worsening or unstable heart failure, or serious ventricular arrhythmias)
- Patients with known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts will be excluded given theoretical (though clinically insignificant) risk of embolization
- Patients with a history of allergy to Lumason will be excluded
Key Trial Info
Start Date :
February 26 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04324294
Start Date
February 26 2020
End Date
December 31 2025
Last Update
December 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048